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Approximately, a third of all colorectal cancer (CRC) is due to inherited susceptibility. However, high-risk mutations in APC, the
mismatch repair (MMR) genes, MUTYH/MYH, SMAD4, ALK3 and STK11/LKB1 are rare and account for o5% of cases. Much of the
remaining variation in genetic risk is likely to be explained by combinations of more common gene variants that modestly increase risk.
Reliable identification of such ‘low penetrance’ alleles would provide insight into the aetiology of CRC and might highlight potential
therapeutic and preventative interventions. In 2003, the National Study of Colorectal Cancer Genetics (NSCCG) was established
with the aim of collecting DNA and clinicopathological data from 20000 CRC cases and a series of spouse/partner controls, thereby
creating a unique resource for identifying low-penetrance CRC susceptibility alleles. The National Cancer Research Network
(NCRN) adopted NSCCG onto its portfolio of trials and 148 centres in the United Kingdom (UK) are now actively participating.
Over 8700 cases and 2185 controls have so far been entered into NSCCG. Our experience in developing NSCCG serves to
illustrate how world-class DNA databases for genetic analyses can be rapidly developed in the United Kingdom.
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Colorectal carcinoma (CRC) is a major cause of cancer-related
mortality in Western countries (Parkin et al, 2003). Evidence from
twin studies indicates that inherited susceptibility is responsible
for B30% of CRC (Lichtenstein et al, 2000). While germline
mutations in APC, the mismatch repair (MMR) genes, MUTYH/
MYH, SMAD4, ALK3 and STK11/LKB1 confer a high risk of CRC,
collectively, such mutations account for o5% of disease (Aaltonen
et al, 2007) with much of the remaining variation in genetic risk
likely to be explained by combinations of more common, lower
penetrance variants. This ‘common disease–common variant’
hypothesis implies that conducting association analyses based on
scans of single nucleotide polymorphisms (SNPs) should be a
powerful strategy for identifying low-penetrance genes (Risch and
Merikangas, 1996; Botstein and Risch, 2003). Such an assertion is
supported by recent data showing an association between 8q24
variants and CRC risk (Haiman et al, 2007; Tomlinson et al, 2007;
Zanke et al, 2007).
Despite much research, few definitive low-penetrance suscept-
ibility alleles have been unequivocally identified through associa-
tion studies. As with many other diseases, positive associations
have been reported for various polymorphisms of genes such as
NAT2, GSTM1, CYP1A1, STK15 and TP53 from small studies, but
few of the initial positive results have been replicated in
subsequent studies (Vinesis et al, 1999; Houlston and Tomlinson,
2001; Ye and Parry, 2003; Borlak and Reamon-Buettner, 2006;
Webb et al, 2006a). The inherent statistical uncertainty of case–
control studies involving just a few hundred cases and controls
seriously limits the power of such studies to identify reliably
genetic determinants conferring modest but potentially important
risks. Hence, the identification of genes associated with CRC
predisposition and determination of their contribution to disease
incidence is, however, contingent on having DNA samples from
large, systematic series of cancer patients.
The National Cancer Research Network (NCRN) was established
to provide support for clinical cancer research in England and is
one of the most substantial and constructive developments in the
area of cancer research to be made in the United Kingdom in
recent years. The NCRN is made up of 40 geographically distinct
Networks covering the entire country (33 in England, 3 in
Scotland, 3 in Wales and 1 in Northern Ireland). Within each
Network there are clinical research support staff and infrastructure
to promote accrual of patients into trials and studies, and the
collection of high-quality clinicopathological data and appropriate
biological samples. Hence, the NCRN presents a major scientific
initiative not only in the field of clinical trials but also in the field
of genetic epidemiology.
To create a resource for identifying low-penetrance predisposi-
tion alleles for CRC, we established the National Study of
Colorectal Cancer Genetics (NSCCG) in March 2003 to collect
DNA and clinicopathological data from 20000 cases. Through
linkage with the NCRN, it has been possible to create a world-class
resource with samples from over 8500 patients in less than 4 years.
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Eligibility criteria
All patients with colon or rectal cancer (International Classifica-
tion of Diseases (ICD) ninth edition codes 153 and 154,
respectively) within 5 years of diagnosis were deemed eligible for
the study. To ensure that data and samples were only collected
from bona fide adenocarcinoma cases histological confirmation of
disease was a prerequisite. The upper limit was initially 75 years at
diagnosis, but this was subsequently reduced to 69 years in the
light of excellent ascertainment to increase the proportion of
younger patients whose cancers are more likely to be due to
inherited susceptibility (Houlston and Peto, 2004). Coupled with
patient recruitment, spouses/partners who had no known past or
current history of malignancy were invited to participate for the
purposes of contributing to the generation of a control series. No
age limit was imposed for these individuals.
Procedural outline
A standardised questionnaire administered to patients is being
used to collect demographic characteristics – sex, date of birth,
ethnic group (White, Black-Caribbean, Black-African, Black-other,
Indian, Pakistani, Chinese, and Other), country of birth and
current area of residence. In addition, detailed identifiable
information is being collected on all first-degree relatives (parents,
siblings and offspring) on cancer diagnoses. An open question is
being used to illicit information on cancer diagnoses in second-
degree relatives. All questionnaires are self-administered and no
surrogate responders were used. Clinicopathological details of
CRCs (site, stage and grade at presentation) were obtained from
the referring clinician using a standardised registration form. For
controls, details of sex, date of birth, ethnic group, place of birth
and current area of residence were collected through a self-
administrated questionnaire. Ethylenediaminetetraacetic acid–
venous blood samples (10–20ml) were collected from all
participants. In addition to blood samples, archival blocks
representative of patients’ CRC were routinely being sought.
Consent forms, questionnaires, registration forms and blood
samples were returned to the Institute of Cancer Research (ICR) by
mail. Blood samples collected were stored at  801C prior to DNA
extraction and quantification. Extraction of genomic DNA from
whole blood is being undertaken by means of either a conventional
salt lysis procedure or Chemagic Magnetic Separation Module 1t
methodology.
Colorectal cancer develops along at least two biologically distinct
pathways characterised by genetic abnormalities, which can reflect
different underlying predispositions (Ilyas and Tomlinson, 1996).
The chromosome instability pathway is typified by chromosomal
abnormalities resulting in loss of heterozygosity and tumour
suppressor gene inactivation, while cancers exhibiting microsatellite
instability (MSI) have defective DNA mismatch repair. In view of
this, we are routinely evaluating CRCs for MSI using the following
methodology: 10mm sections are cut from formalin-fixed paraffin-
embedded tumours, lightly stained with toluidine blue, and regions
containing at least 60% tumour are micro-dissected. Tumour DNA is
being extracted using the QIAamp DNA Mini kit (Qiagen, Crawley,
UK) according to the manufacturer’s instructions and genotyped for
the mononucleotide microsatellite loci BAT25 and BAT26, which are
highly sensitive markers of MSI (Zhou et al, 1998). Samples showing
novel alleles at either BAT26 or BAT25 or both markers are assigned
as MSI (corresponding to a high level of instability, MSI-H Boland
et al, 1998).
Statistical considerations
The primary aim of establishing NSCCG was to generate a DNA
resource of CRC patients of sufficient size to robustly identify
low-penetrance alleles by association studies of genetic poly-
morphisms. From the outset, it was envisaged that such searches
would be conducted on a genome-wide basis. It is well-recognised
that as such studies involve genotyping a vast number of markers,
a large number of false-positive associations will inevitably be
generated and only a small number will be truly associated with
disease susceptibility. Hence, associations need to attain a high
level of statistical significance to be established beyond reasonable
doubt and significance levels of B10
 7 have been proposed as
being appropriate (Risch and Merikangas, 1996). The original
target of NSCCG was to assemble a series that will include 2000
cases. This figure had been based upon contemporaneous
preconceptions on the probable impact of common alleles on
disease risk. Recent data from association studies, however,
indicate that common disease alleles are likely to be associated
with risks typically o1.5 (Easton et al, 2007; Gudmundsson et al,
2007; Haiman et al, 2007; Tomlinson et al, 2007; Zanke et al, 2007).
To identify alleles conferring such risks to have 80% power-
stipulating statistical thresholds of 10
 7 necessitates having access
to sample sets of at least 10000 cases and 10000 controls. These
statistical considerations led us to significantly revise our target
sample size to ensure that we would generate a resource adequately
powered to identify such disease-causing alleles and to examine for
epistatic interactions.
Ethical considerations
In generating DNA registries, ethical considerations are central to
study design. One of the particular strengths of studies such as
NSCCG is that once constructed the DNA database can be probed
repeatedly for different existing and newly identified candidate
risk factor genes. It is not feasible to contact all study entrants to
seek further written consent for each specific test, therefore, the
information sheet study discussion and consent is centred on
the general concept of ‘genetic analyses’. As these investigations
were to be solely for research to find new gene(s) predisposing to
cancer, it was implicit that no individual results will be conveyed to
persons. In publications of findings no study entrant would be
identifiable. As with all studies of this nature, we clearly stated that
if a study entrant wished to withdraw, then their DNA sample and
all information held on them would be destroyed. To ensure
confidentiality, data are held under secure conditions at the
Institute of Cancer Research (ICR) in accordance with the Data
Protection Act (1998).
All clinical information and biological samples were obtained
only after fully informed consent was obtained from participating
individuals, and in accordance with the tenets of the Declaration of
Helsinki. Ethical approval for the study was obtained from the
Multi-Centre Research Ethics Committees (MREC/98/2/67;
MREC02/0/97).
RESULTS
After securing ethical permissions at national level through the
Multi-Centre Research Ethics Committee, the study was incorpo-
rated into the NCRN (National Cancer Research Network) portfolio
in March 2003. It was subsequently rolled out across England after
individual hospitals had obtained relevant local ethical permissions.
As the number of centres becoming active participants in NSCCG
widened, accrual of both patients and controls significantly
increased (Figure 1). Currently, 148 sites are participating in
NSCCG (Figure 2) and recruitment stands at approximately 160
cases and 40 controls per month. Although most hospitals entering
subjects into NSCCG are located in England, centres in Wales and
Northern Ireland are now participating and a number in Scotland
are in the process of gaining local ethical permissions to participate,
thereby, making the study UK-wide.
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collected from 8722 cases and 2185 controls. The NSCCG collection
will continue until samples from 20000 CRC cases has been
assembled. The number of male patients ascertained or included
(59% of cohort) reflects the slight sex preponderance of the
disease. In terms of ethnicity, over 90% of patients entered into
NSCCG were self reported as White Caucasians. Although controls
were of similar age in comparison to cases (mean age 59 years;
s.d.¼9.5) and 90% were self-reported as White Caucasians not
surprisingly, the majority (64%) were female.
A high proportion of the cases have been diagnosed at a young
age, reflecting the criterion for ascertainment (Table 1); specifi-
cally, 29% of the cases were aged o55 years old at diagnosis,
compared with o10% in the general population. Approximately
15% of patients have a family history of CRC defined by having at
least one affected first-degree relative. The 60:40 ratio of colonic
(ICD 153) to rectal disease (ICD 154) of cases recruited to date is in
keeping with that observed in the general UK population (Table 1).
Similarly, stage at presentation is comparable to that generally
observed. To date, 3088 tumour blocks have been collected and
2516 evaluated for MSI; 12% showing MMR deficiency, concordant
with the frequency of this phenotype in unselected CRC (Storojeva
et al, 2005).
DISCUSSION
Over the coming years our expanding knowledge of cancer
genetics will have a major impact on our ability to predict an
individual’s level of risk of developing cancer, detect and
diagnose cancer early and select treatments which are most
likely to be effective. Ultimately the genetic revolution may lead
to ways of preventing cancer. Advances in genetics will lead to a
greater understanding of inherited susceptibility to cancer. The
relative influence of genes on cancer development is variable
and ranges from situations where genetic factors predominate
and are highly predictive of disease development, to others
where they play only a minor role in modifying the effect of
environmental exposure to toxic substances.
(NHS Cancer Plan, 2000)
Following the sequencing of the human genome, large-scale
harvests of SNPs have been conducted, and there are currently
410 million documented human SNPs (dbSNP). Patterns of
linkage disequilibrium (LD) between polymorphisms have been
characterised allowing subsets of tagging SNPs to be selected that,
through LD with other variants, capture a large proportion of the
common sequence variation in the human genome. These
comprehensive sets of tagging SNPs, which capture most of the
common sequence variation, coupled with the development of
highly efficient analytical platforms allow whole-genome studies
for disease associations to be conducted cost effectively. This
approach is unbiased and does not depend upon prior knowledge
of function or presumptive involvement of any gene in disease
causation. Moreover, it avoids the possibility of missing the
identification of important variants in hitherto unstudied genes or
regions of the gene-harbouring and gene-controlling elements. The
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Figure 1 Accrual rate of patients and controls to NSCCG.
Figure 2 Sites of centres in the United Kingdom recruiting to NSCCG as
of March 2007.
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thus, now open for further exploration.
Here, we have demonstrated that the centralisation of cancer
services in the United Kingdom offers an opportunity to establish
large, well-characterised cohorts by targeting collection to the largest
centres. Moreover, mobilising NCRN networks provides a means of
consistently delivering the data and sample collection needed to
complete genetic epidemiology studies on the required scale.
Ascertainment of cases through NCRN has been directed
towards those diagnosed at young age and this serves to empower
the resource for identifying disease-causing alleles by virtue of
genetic enrichment. The possibility of population stratification
leading to false inference of disease–genotype association can be
addressed by adjusting for known region/ethnicity or by using
information on unlinked genetic markers. In NSCCG, the
geographical area of birth and area of residence within the United
Kingdom is known for all of the individuals, and this information
can be used to allow analyses stratified by region of residence,
reducing any effects of population stratification.
For some analyses, family history information on cancer
diagnosis in relatives is required. In our study, participants are
providing information on cancer diagnosis in relatives without
verification of the diagnosis through medical sources or health
records. Subject to ethical approval, there is a possibility of
verifying cancer diagnoses verified through national registries.
While such verification is theoretically desirable since studies have
shown that CRC patients correctly report B80% of positive family
histories and 495% of negative family histories in first-degree
relatives (Aitken et al, 1995; Ziogas and Anton-Culver, 2003), self-
reported data still has great utility and is unlikely to systematically
bias many types of analyses.
As blood samples have been ascertained from many clinical
centres in the United Kingdom, we are cognisant of the potential
problem of differential bias in genotyping. We have however, no
evidence of differences in DNA quality as we have previously
documented call rates of 99.8% in 1526 of samples ascertained
through NSCCG (Webb et al, 2006b).
The NCRN research networks are established within cancer care
networks where access to partners is readily available and direct.
They are not designed to collect samples from the general
population or the unrelated population so our choice of collecting
samples from partners was a pragmatic one appropriate for the
NCRN. Inevitably, in studies such as NSCCG, a smaller number of
samples from controls will be collected than from cases since in
addition to lack of compliance many patients do not have a current
partner. While the sex of controls ascertained through initiatives
such as NSCCG will usually be of the opposite gender to cases by
pooling samples from other similar studies, it is possible to
develop large control data sets such as a 1958 Birth Cohort
established in the United Kingdom currently being used by the
Wellcome Trust Case Control Consortium (WTCCC). Because of
the difficulty of obtaining sufficiently detailed and accurate data on
environmental exposure in studies such as NSCCG, and because
there are issues to do with comparability of exposure data from
controls assembled from different studies, it is acknowledged that
studies of environmental risk factors including gene–environment
interaction will be limited in resources such as NSCCG.
Given the projected size of NSCCG, the main value of collections
such as this will be in studies of common genetic risk factors and
gene–gene interactions, hypotheses regarding gene–environment
interaction will require alternative data sets. Accepting the
limitations of NSCCG, our experience in developing this resource
serves to illustrate how large DNA databases for genetic analyses
can rapidly be developed in the United Kingdom.
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Table 1 Clinicopathological characteristics of colorectal cancer patients
recruited to the National Study of Colorectal Cancer Genetics
Number of patients (%)
Total 8722
Gender (male/female) 5175 (59%):3547 (41%)
Age at diagnosis (years)
o30 63 (0.1%)
31–35 75 (0.8%)
36–40 174 (2.0%)
41–45 329 (3.8%)
46–50 613 (7.0%)
51–55 1234 (14.2%)
56–60 1981 (22.7%)
61–65 2316 (26.6%)
66–69 1745 (20.0%)
70+ 192 (2.2%)
Mean (SD), Median 58.8 (8.4), 60
Ethnicity
Asian 59 (0.7%)
Bangladeshi 1 (o0.1%)
Black-African 20 (0.2%)
Black-Caribbean 56 (0.7%)
Black-Other 8 (o0.1%)
Indian 69 (0.8%)
Jewish-Ashkenazi 18 (0.2%)
Jewish-Sephardic 1 (o0.1%)
Pakistani 13 (0.2%)
White 8477 (97.2%)
Type of colorectal cancer
Colonic disease (ICD-9 153) 5247 (60%)
Ascending 747
Hepatic flexure 159
Splenic flexure 178
Transverse colon 391
Descending colon 338
Sigmoid colon 2337
Caecal 1035
Other/not specified 62
Rectal disease (ICD-9 154) 3475 (40%)
Recto-sigmoid junction 509
Ampulla 2962
Other/not specified 4
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